Deleted in bladder cancer 1 (DBC1) is a candidate gene for the bladder tumour suppressor locus at 9q33.1. The function of the gene is currently unknown but a crossspecies sequence comparison suggests an important role, as it is highly evolutionarily conserved. Here, we transfected a nonexpressing human bladder cancer cell line with a set of human DBC1 cDNA constructs. The effect on global expression patterns was assessed using cDNA microarrays. The cell clone with the lowest level of DBC1 expression showed induced expression of 26 genes including plasminogen activator inhibitor 2 (SERPINB5; 4.6-fold), heparin-binding EGF-like growth factor precursor (DTR; 4.2-fold), small proline-rich protein 2B (SPRR2B; 3.6-fold), metallothionein 1 isoforms (MT1B/ MT1A/MT-1F; from 2.9-to 3.2-fold), tissue-type plasminogen activator precursor (PLAT; 2.8-fold) and urokinase-type plasminogen activator precursor (PLAU; 2.7-fold). In clustering analysis, both PLAT and PLAU clustered with the functionally related urokinase plasminogen activator surface receptor (PLAUR; 1.9-fold). Furthermore, 14 human bladder tumours were analysed by real-time quantitative PCR using gene-specific primers for selected (n ¼ 20) genes. The expression levels of SERPINB5, PLAU, PLAUR and MT1 correlated with the DBC1 levels, suggesting previously unknown involvement of DBC1 in the urokinase-plasminogen pathway.
Introduction
The common feature shared by the vast majority of bladder cancers is that they have deletions of chromosome 9. Over the years, multiple candidate regions have been reported (reviewed in Knowles, 1999) . The deleted in bladder cancer 1 (DBC1) gene, originally named DBCCR1, which represents a candidate tumour suppressor gene within a precisely mapped region of loss of heterozygosity on 9q33, shows loss of one allele in B60% of all bladder tumours and homozygous deletion or transcriptional silencing by promoter hypermethylation in many cases (Habuchi et al., 1997 (Habuchi et al., , 1998 Nishiyama et al., 1999; Fujiwara et al., 2001; Stadler et al., 2001; Williams et al., 2002) . It has been suggested that hypermethylation of DBC1 is one of the earliest events in the development of transitional cell carcinoma (TCC) (Habuchi et al., 2001) . Recently, loss of DBC1 expression by promoter hypermethylation was reported during transformation of adult mesenchymal stem cells (hMSC) transduced with the hTERT gene (Serakinci et al., 2004) , where methylation correlated with the acquisition of the tumorigenic phenotype. Thus, DBC1 alteration might be one of the essential changes during neoplastic development in hMSC.
Recently, homologues of DBC1 have been found in Mus musculus (96% amino-acid identity), Rattus norvegicus (96% amino-acid identity) and several other organisms including Danio rerio, suggesting universal importance of this gene. In brain and spinal cord, DBC1 expression is high and some of the homologues have been reported as bone morphogenetic protein-2/retinoic acid-inducible neural-specific proteins (Kawano et al., 2004; Toshiyuki and Ichiro, 2004) . Structurally, DBC1 harbours a membrane-attack complex (MAC)/perforin protein domain that, in the context of the perforin protein, is involved in pore formation during complementmediated cell lysis. However, to date, there is no evidence for an equivalent function of DBC1. Our previous studies have shown that re-expression of DBC1 in bladder tumour cells has an antiproliferative effect, but this does not appear to be due to a direct effect on apoptosis (Nishiyama et al., 2001) . Recently, Wright et al. (2004) reported that DBC1 mediates cell death in cultured bladder tumour cells with a mechanism which is not of the classic apoptotic type. The same research group previously reported that acid sphingomyelinaselike protein (SMPDL3A; alternatively called ASML3a) is upregulated by DBC1 (Wright et al., 2002) . At present therefore, the exact gene function of DBC1, its mechanism of action and the pathways involved have not been solved.
In this study, we have re-expressed DBC1 in a human bladder cancer cell line that shows hypermethylationinduced silencing of the endogenous DBC1 gene. Cell clones expressing various levels of full-length and truncated forms of the DBC1 protein were created. RNA from these clones was analysed using cDNA microarrays and the data were normalized against the vector controls. Thus, the differential gene expression should be directly related to ectopic DBC1 expression. Based on these microarray results and advanced clustering, a set of genes was selected for further analysis using quantitative real-time reverse transcriptase-PCR (qRT-PCR) and Western blotting.
Results

Establishment of DBC1-expressing clones
Four stable transfectant clones (B, C, D and H) containing full-length (FL) and two containing truncated DBC1 expression constructs (TA1 and TA4) were chosen ( Figure 1, panel a) . The effect of DBC1 on proliferation of transfected clones was assessed by cell counts over a 14-day period. All transfected cell lines demonstrated inhibition of population growth but increased cell death was not observed. Clone B showed the greatest inhibition compared to the parental cell line. After 2 days, the inhibitory effect on clone B was nearly 50% and after 7 days more than 75%. We and others (Wright et al., 2004) have attempted to generate TCC cell lines with inducible DBC1 expression with no success, which indicates that even low-level DBC1 expression may be extremely toxic in some situations.
From the set of truncation constructs ( Figure 1 , panel a), TA1 was selected because, compared to FL-DBC1, it had a pronounced inhibitory effect on colony formation and cell proliferation in NIH-3T3 cells and the bladder cancer cell lines 5637 and T24 (data not shown). This truncation is dominated by the MAC/perforin domain sequence. The second gene truncation used, TA4 (582 bp), covers the rest of the DBC1 gene, including a cysteine-rich domain at amino acids 260-278. This truncation has an inhibitory effect on cell proliferation, although less than truncation TA1 or FL-DBC1.
The Sanger cDNA microarrays contain two different DBC1 cDNA clones, which both gave very similar results for all FL-DBC1 cell lines. However, the TA1-transfected cell line showed no hybridization with one of the DBC1 cDNA clones on the array (32205_A), so we suspected that this cDNA clone has a truncation in the 5 0 region. The resequencing data proved this assumption to be correct. The TA1 truncation ends in exon 3, whereas the sequence of this clone starts near the end of exon 4. Gene lists: up-and downregulated genes Our hypothesis was that all FL-DBC1-expressing clones would be similar and would share some properties with clones expressing particular regions of the protein that might allow region-specific functions to be mapped. This hypothesis evolved as the data were analysed further. The expression data were compared with the vector control data and lists containing twofold over/underexpressed genes were compiled for all experiments (Table 1) . Genes up/downregulated in the vector control and those that did not pass the statistical group comparison (Benjamini-Hochberg, P ¼ 0.01) were excluded. The expression data for two selected truncations (TA1, TA4) were filtered to exclude genes that were simultaneously overexpressed or underexpressed in transfectant clones expressing each truncation. Thus, this approach produces gene lists, which reflect the expression changes specifically related to each truncation ( Figure 1 , panel b). All these genes are among those discovered using the DBC1 clone B data and twofold filtering ( Table 1 ), suggesting that they are down/ upregulated by either of the DBC1 variants. The plain numbers of up/downregulated genes were plotted for each clone (Figure 2 , panel a, bars). DBC1 clone B, which has the lowest level of DBC1 overexpression ( Figure 2, panel a, lines) , created the largest number of differentially expressed genes. Consensus lists were constructed to find the common genes altered in two or more clones (Figure 2, panel b) . The upregulated genes in the consensus lists suggest that clone H is different from clones B, C and D. These data demonstrate that modest DBC1 re-expression, as in clone B, is enough to induce a large number of expression alterations, and that these changes are similar to changes induced by clones with higher DBC1 expression.
To find the statistically most robust genes, the data from all experiments were subjected to a statistical group comparison using ANOVA with BenjaminiHochberg False Discovery correction with P-value cutoff 2.0 Â 10 À5 . This resulted in a list of 19 cDNA clones (13 genes) and the likelihood for any one of these genes being selected by chance is virtually nonexistent (0.002%) (Supplementary Table 1 ). Among these genes are both tissue-type plasminogen activator precursor (PLAT) and plasminogen activator inhibitor 2 precursor (SERPINB5), IGFBP3, and LAM5 (lysosomal-associated multispanning membrane protein-5; alias retinoic-acid inducible protein E3), most (14/19) of which were also in the twofold lists (Table 1) .
Clustering: experiment and gene trees, k-means and self-organizing maps (SOM) Experimental and hierarchical gene trees were plotted using genes that had shown at least twofold over or underexpression in one of the clones (Figure 3 ). These trees revealed rather striking similarity between DBC1 clones B, C and D, suggesting once again that clone H is different. Clones B, C and D clustered together in the experiment tree, whereas clone H formed a cluster with TA1. To create a consensus view of multiple clustering methods, the trees were combined with the results of a 3 Â 4 SOM (12 clusters) and k-means clustering analysis. After vigorous testing the k-means, k ¼ 16 was selected for final clustering, producing 16 defined clusters and one unclassified cluster. To add a common reference point and emphasize the advantages of the more complex analysis methods, all clustering data were coloured according to the basic k-means (n ¼ 5) cluster they belonged (Figure 3, colour code 2) .
Clustering by all three methods appeared to be linked to the expression pattern of clone B. For example, 27/28 cDNA clones underexpressed in clone B belonged to SOM cluster (1, 4) and k-means (16) cluster 16. In hierarchical clustering, the majority (26/28) of these belonged to one larger gene cluster containing 29 cDNA clones in total. Furthermore, all clones in the k-means (16) cluster 3 and SOM-cluster (1, 1) were overexpressed in clone B. Cluster 3 had 27 cDNA clones, which are mostly involved in plasminogen activation and apoptosis; PLAT, PLAU and PLAUR, two interferon-induced/ stimulated genes, two copies of DAP-1 and multiple copies of small proline-rich proteins 1B/2B. The PLAUR gene is not on our initial twofold list as it was filtered out, which demonstrates the importance of clustering.
One of the most striking clusters was k-means cluster 10, which had nine metallothionein 1 isoforms. These metallothioneins had a distinct expression pattern, in all cells expressing full-length clones and truncations. Other k-means clusters were designated as response to wounding, response to inflammation and mesoderm development/epidermal differentiation, based on the gene ontology annotation. These data are visualized in Figure 3 . Examination of the GO groups represented in the clusters and in the list of significant genes did not implicate specific pathways (Supplementary Table 2 ).
Principal component analysis (PCA)
For nonfiltered data, a total of seven components was identified. The three most significant components were analysed further. In the most significant PCAtrend, FL-DBC1 transfectant clones B, C and D showed overexpression, with C being the weakest of these three. The second most significant expression pattern followed the level of DBC1 expression, clone B being now underexpressed. The third most significant trend was inversely related to DBC1 gene expression in clones B, C and D.
Similarity analysis
Gene similarity analysis was applied to several at least twofold up-and downregulated genes. Most of the genes tested had similar expression to genes that were found using clustering analysis. Interestingly, the most similarly expressed gene to MT-1F was arginase (CC ¼ 0.97; 1.6/0.90/1.68-fold), which is part of the nitric oxide biosynthesis pathway associated with metallothioneins. In general, the expression of metallothioneins was similar to the expression pattern of IL-1b and various small proline-rich proteins (SPRRs) (Figure 3 ; line chart, top right).
Consensus genes, excluded genes
The statistical filter we used for twofold lists in Table 1 generates a very conservative list of genes. Important genes could be masked by factors causing variation of expression (experimental or biological). For this approach, we decided to monitor the individual t-tests of cell clones instead of statistical filtering of all data. We predicted that genes that are induced by FL-DBC1 but are not under feedback control should form a consensus list. Since the hierarchical gene clustering suggested that clones B, C and D were related, these cell clones were selected for consensus analysis. They were filtered for genes simultaneously twofold over-or underexpressed in Next, genes up-or downregulated (o0.75) in B, C and D cell clones but not differentially expressed (0.75-1.25) in clones expressing truncated DBC1 or in controls were selected. This filter selects those genes that are exclusively controlled by full-length DBC1. Four genes passed this filter: ID-1 (0.43/0.61/0.61-fold), which is a transcriptional regulator; retinoic acid receptor a RXRA (0.47/0.54/0.73-fold); homeobox protein MEIS2 (0.55/0.71/0.71-fold) and cysteine desulfurase NFS1 (0.66/0.67/0.68-fold). The equivalent list for upregulated genes had 62 cDNA clones, of which nine genes had more than twofold expression in clone B: PLAU, PLAT, CDC42, SOD2, DTR, DAP-1, SGK, vimentin and natural killer cells protein 4. All these genes are among those genes listed in Table 1 .
Consensus analysis of genes up/downregulated (twofold) in clone B and by either of the truncations led to empty gene lists, that is, suggesting that the full sequence is needed for full functionality of DBC1.
Senescence
As several genes in the twofold upregulated list have been found to be upregulated in senescent cells, a senescence-associated marker (b-galactosidase staining at pH 6) was assessed in the transfectants. This enzyme is active only in senescent cells and is not found in quiescent or immortal cells. Furthermore, we measured the expression levels of Claudin-1, which is a senescenceassociated epithelial membrane protein, using qRT-PCR. Both approaches led to negative results, that is, we could not detect any b-galactosidase activity nor differential Claudin-1 expression between controls and the DBC1-transfected cells. Cell clones containing DBC1 were slightly more sensitive to ceramide C 6 , which is a well-known senescence inducer (data not shown). However, the result of senescence-specific staining was still negative. Ceramide C 2 had no detectable effect on the cells.
Verification of microarray results
Expression of 10 well-known housekeeping genes in various relevant tissues (bladder cell lines, normal human urothelium and bladder tumour samples) was preassessed, and based on the stability measure described by Vandesompele et al. (2002) , the three best genes (SDHA, GAPDH, HPRT) were selected for use in normalization.
To validate the microarray results, assays for 20 genes selected mainly from the twofold list of clone B were designed (Table 1; column far right; Supplementary  Table 3 ). In addition to the original RNA used for array hybridization, new RNA samples were isolated from transfected cell clones regrown from frozen stocks. This ensured that any differential expression detected with both detection systems represents a real biological phenomenon, and not merely an intrinsic property of a certain RNA population at a given moment.
The microarray results from the cell line 5637 were compared with both Western blots and qRT-PCR results (Figure 4, panels a and b) . The most detailed 
Gene expression in bladder tumours
The expression of the 20 gene set was also analysed in 14 low-stage, low-grade human bladder tumour samples. Compared to normal human urothelium (NH 4 ), 64% had lost or at least had reduced DBC1 expression ( Figure 5 ). Our aim was to find genes with linked expression to DBC1. Genes that did not follow the trend in all samples with reduced DBC1 expression were rejected. The expression levels of SERPINB5, PLAU, PLAUR and all MT1 isoforms were found to follow the measured DBC1 expression levels in all tumour samples with reduced DBC1 expression analysed. These genes also followed the overexpression of DBC1 found in three tumours in all but two cases (PLAUR in tumour 591 and MT1 in tumour 468). Furthermore, these results were also in line with the cDNA microarray results, that is, DBC1 overexpression in tumour samples had the same gene-specific effect on expression as it had on the model cell line.
Discussion
Presently, the most striking structural feature of DBC1 is the MAC/perforin domain (amino acids 72-251). This feature is shared by the perforin protein and the MAC components of the complement system that disrupt the phospholipid bilayer of target cells, resulting in cell lysis and death. To date, there is no evidence that DBC1 performs this perforin domain-related function, no significant features have been identified in the remainder of the protein and no significant homology with other proteins has been detected outside the perforin domain. However, human DBC1 has highly conserved homologues in mouse, rat and several other organisms, indicating the likely functional significance of all regions of the protein. In Rattus norvegicus, the gene was identified as a bone morphogenetic protein/retinoic acid-inducible transcript in the brain and is involved in perinatal development of sympathetic neurons (Kawano Toshiyuki and Ichiro, 2004) . DBC1 expression is lost by promoter hypermethylation in bladder tumours, hepatocellular carcinomas and during transformation in hMSC transduced with the hTERT gene, indicating an important tumour suppressor role in addition to its role in the developing nervous system (Habuchi et al., 1998; Yu et al., 2003; Serakinci et al., 2004) . Thus, DBC1 could have multiple functions in eukaryotic cells. The present study was designed to identify clues to the function of the human DBC1 from analysis of its effects on the transcriptome. We have identified genes whose expression is altered in bladder tumour cells upon re-expression of DBC1, several of which cluster in groups that have predicted biological relationships. Based on the various clustering exercises, DBC1 expression levels, and growth properties in the four full-length DBC1-transfected clones analysed, we deduced that clone B is likely to have the closest resemblance to the relevant physiological situation. Since this clone had the lowest DBC1 expression, we postulated that the observed expression changes are more likely to be linked to relevant DBC1-induced effects, and less likely to represent stress/inflammatory responses.
Metallothionein (MT) 3 and various isoforms of MT1 formed one of the most striking patterns in our arrays as a family of genes, varying uniformly from overexpressed in FL-DBC1 transfectant clone B to underexpressed in clones expressing the truncation TA1. All MT1 isoforms and MT3 were also downregulated by the TA1 truncation. MT3 has been reported to be upregulated in bladder cancers and associated with grade (Sens et al., 2000) . Similarly, expression of MTs 1 and 2 has been associated with aggressive behaviour of bladder tumours (Ioachim et al., 2001) . MTs are known to regulate apoptosis, the release of mediators such as nitric oxide and the binding of heavy metals such as zinc and cadmium (Hamada et al., 1996; Tsangaris and Tzortzatou-Stathopoulou, 1998; Simpkins, 2000) . Our measured expression levels of arginase II (ARG2) (Figure 3 , top right panel), a gene involved in nitric oxide biosynthesis, followed the MT expression levels and ranked highest (0.997) in the expression similarity analysis of MT1F. The highest level of MT overexpression was measured in the clone expressing lowest levels of DBC1, clone B.
Three interleukin-related genes on the microarray showed changes in expression pattern that related very closely to the expression patterns of MTs (Figure 3 , top right, IL1B). One of these genes was IL1B which is known to induce MT synthesis (Kondo et al., 1994) . Expression of IL1B-binding protein precursor (IL-1BBP) was a mirror image of IL1B gene expression. A threefold overexpression of DBC1 (clone B) was sufficient to induce 3.5-fold increase in IL1B levels whereas the TA4 truncation of DBC1 specifically downregulated IL1B more than two fold. IL1B has been reported to regulate expression of cellular retinoic acidbinding protein type II (CRABP II) and small, prolinerich protein 1 (SPRR1) (Eller et al., 1995) . Two members of the cellular retinoic acid-binding proteins (CRABPs) exist in the cytosol for specific binding to retinoic acid (RA), designated as CRABP-I and CRABP-II. In the parental cell line 5637, CRABP-I has been previously reported as nonexpressed (Hurst et al., 1999) . In line with this report, we measured CRABP-I expression, which was just above the detection level of the microarrays in all clones, whereas CRABP-II was expressed at much higher levels and 2.2-fold overexpressed in clone D. Furthermore, the expression profiles of small, proline-rich proteins (SPRR1B and SPRR2B) were nearly identical to the expression profile of MTs and SERPINB5 (Figure 3 , top right panel). SPRR1B is induced during keratinocyte differentiation and is downregulated by retinoids (Marvin et al., 1992) . Retinoid signalling has been suggested to be a frequent target of inactivation in bladder carcinogenesis (Hurst et al., 1999) .
Components of plasminogen activation have been linked to bladder cancer, as reviewed in Hasui and Osada (1997) . In a rat bladder in vitro model, the importance of the urokinase system for bladder cancer invasion has been demonstrated by using PLAU pathway antagonists (Fujiyama et al., 2001) . SERPINB5 can form a complex with PLAU (Jensen et al., 1994) . SERPINB5, the surface receptor of PLAU (PLAUR) and the tissue-type plasminogen activator PLAT were overexpressed in clones B, C and D with highest expression in clone B. In human bladder tumours, we found that the levels of PLAU, PLAUR as well as SERPINB5 followed DBC1 expression levels. In Rat-1 cells, activated HRAS induced SERPINB5 gene expression 10-15-fold (Cohen et al., 1989) . In these cells, PAI-1 and SERPINB5 were found independently regulated. This is in agreement with our results where SERPINB5 was fourfold overexpressed in clones B and D, whereas PAI-1 expression was unchanged (clone D) or nearly unchanged (clone B, 1.4-fold). SERPINB5 was also found specifically downregulated by the TA1 truncation. SERPINB5 has been identified as a biomarker for several cancer types, including bladder (Cohen et al., 1989; Foucre et al., 1991; Hudson and McReynolds, 1997; Champelovier et al., 2002) . SERPINB5 is synthesized in two forms originating from single mRNA species, an intracellular nonglycosylated form (46 543 kDa) and an extracellular glycosylated form (60 kDa) (for a review, see (Bachmann, 1995) ). During apoptosis, SERPINB5 is modified leading to reduced molecular weight (Jensen et al., 1994) . We detected the 47 kDa nonglycosylated (intracellular, lysates) and the 60-70 kDa glycosylated (secreted) forms of SERPINB5 using Western blotting (Figure 4, panel c) . SERPINB5 has been reported as an upregulated gene in senescent dermal fibroblasts cells (Shelton et al., 1999) along with MT-1E, PLAU, PLAT, IL1B, IGFBP3 and superoxide dismutase (SOD2), which were all differentially expressed in our experiments (Table 1) . Similarly, MT-2 and TFPI-2 (2.2-fold upregulated in DBC1 clone B) were identified as overexpressed during ras-induced senescence (Barradas et al., 2002) . This may indicate that the changes we have observed are related to the reimposition by DBC1 of a stimulus that has the same effect as inappropriate oncogenic signalling and imposes features of a senescent-like growth arrest. However, at present, we have not been able to gain any clear experimental support for this.
A recent study identified ASML3a (acid sphingomyelinase-like phosphodiesterase 3a) as a binding partner of DBC1 (Wright et al., 2002) . Using transient transfection of bladder tumour cell lines, they demonstrated that DBC1 overexpression resulted in the upregulation of ASML3a RNA and protein expression. Our microarrays contain two copies of ASML3a, but their expression was unchanged in all transfectants and controls and remained very low and close to the detection minimum. Also, in bladder tumours, the ASM3La levels were virtually unchanged (data not shown). It is not known whether this protein has a sphingomyelinase activity. However, we assessed the possibility that DBC1 alters the intracellular levels of ceramide and/or sphingosine. We tested the sensitivity of DBC1-expressing cells to C 6 -ceramide, which induces expression of b-galactosidase (Mouton and Venable, 2000) . In our preliminary experiments, the DBCexpressing cells showed increased sensitivity to ceramide C 6 but no change in b-galactosidase activity.
Loss or silencing of DBC1 is predicted to be a key event in bladder cancer development. We have shown previously that the parental cell line used in this study (5637) has retained heterozygosity at many of the microsatellite alleles neighbouring DBC1, and that there is hypermethylation of the promoter region of this gene such that we could not detect the protein product in Western blots and RT-PCR detected no mRNA in the untransfected cell line (Habuchi et al., 2001; Williams et al., 2002) . The restoration of DBC1 expression, as described here, restored the regulation of genes, which are normally suppressed by DBC1. Many of the differentially expressed genes induced by DBC1 are components of the plasminogen pathways. In proliferation assays, one of the truncations (TA1; 1-246 aa) demonstrated enhanced growth suppression, suggesting essential function within this fragment. However, cDNA microarray analysis of the truncations suggests that the entire coding sequence is required for full functionality. Furthermore, we have also discovered a handful of genes down/upregulated specifically by these aberrant forms of DBC1. These are attractive binding partner candidates for DBC1. Two of these genes, MT1 and SERPINB5, were associated with the DBC1 expression levels of bladder tumours. In addition to SERPINB5, two other genes of the urokinase-plasminogen pathway, PLAU and PLAUR, were also linked to DBC1 levels of tumours. Although these genes have been implicated in various cancer types, they have not previously been linked to the mode of action of the DBC1 tumour suppressor gene.
Materials and methods
Cell culture, growth curves and transfections
The human transitional cell carcinoma cell line 5637 (ATCC) was cloned and a single clone was used for transfection with cDNA expression constructs encoding the full-length cDNA or truncated versions of DBC1 in the vector PM-KIT/HA-neo (Nishiyama et al., 2001) . Stable clones were selected and expanded in RPMI 1640 medium, with 10% fetal calf serum, 2.4 mM L-glutamine and 400 mg/ml G418 in an atmosphere containing 5% CO 2 . Four clones containing the full-length DBC1 cDNA (designated as clones B, C, D and H), a mass population of cells containing the vector only with HA tag (control) and two clones containing truncations TA1 and TA4 were used (Figure 1; panel a) . Growth curves were performed by plating 1 Â 10 5 cells per 6 cm dish on day 0 and counting duplicate dishes until confluence. Normal human urothelial cells were cultured as described (Hurst et al., 2004) .
RNA preparation from tumour tissue
Bladder tumour tissue samples obtained from consenting patients were immediately frozen in liquid nitrogen. Frozen sections were cut and assessed for tumour cell content. Only samples with >90% tumour content were used for RNA extraction. Total RNA was extracted from 10 Â 20 mm tissue sections using a PicoPuret RNA Isolation kit (Arcturus Bioscience, CA, USA). In total, 300 ng of RNA was used in reverse transcription reactions containing 250 ng random primer (Invitrogen, Paisley, UK), 0.5 mM dNTPs, 40 U RNase OUT (Invitrogen), 10 mM DTT, 1 Â first strand buffer and 200 U SuperScriptt II reverse transcriptase (Invitrogen).
RNA isolation, cDNA microarrays and scanning
The standardized RNA isolation, cDNA labelling and hybridization protocols of The Sanger Institute were used for all preparations (www.sanger.ac.uk/Projects/Microarrays/arraylab/methods.shtml). Four technical replicates per each transfectant were analysed using cDNA arrays. Expression data of the transfected cell lines were compared to the parental cell line. Reciprocal labelling was applied to avoid dye-specific bias. All transfectants were compared to the parental cell line and genes differentially expressed in vector controls were rejected to abolish nonspecific expression alterations. For scanning and quantification of microarrays, a Packard Biosciences Scanarray 4000 confocal scanner was used (Perkin-Elmer LifeSciences, Cambridge, UK).
Data mining and filtering GeneSpring v6.0 software was used for data mining and filtering, and Microsoft Excel was used for data conversions and matrix manipulations. For statistical confidence filtering of fold change, Benjamini-Hochberg False Discovery correction was applied with t-test P-value of 0.01 (except for Supplementary Table 2; P ¼ 2.0 Â 10 À5 ). All samples were replicated four times, and the HA vector control sample was applied to identify nonspecific signals, that is, the HA control sample represents the HA-vector/parental cell line ratio.
Immunoblotting
For Western blots, cells were lysed at 80% confluence in ESB buffer (0.12 M Tris-HCL, pH 6.8; 20% glycerol; 4% SDS), scraped and the total protein was assayed using the Bradford method (Bio-Rad, Hemel Hempstead, Herts, UK). In total, 20 mg of total protein was run in 12.5% denaturing polyacrylamide gels and transferred to Hybond ECL nitrocellulose (Amersham Biosciences, Buckinghamshire, UK). The primary antibody for DBC1 detection was mouse anti-HA12CA5 (Cancer Research UK). Blots were blocked with 4% MPS (Bio-Rad). Amersham ECL reagents (Amersham Biosciences, Buckinghamshire, UK) were used for detection. For SER-PINB5 detection, a goat anti-human antibody (375G; American Diagnostica) was used with rabbit anti-goat secondary antibody and the Odyssey Li-COR Imaging System (LI-COR Biosciences, Cambridge, UK) was used for quantitation.
Quantitative real-time RT-PCR To verify the microarray results, the transfectant clones were regrown and new RNA was prepared, and cDNA was prepared using the standard microarray protocol (www. sanger.ac.uk/Projects/Microarrays/arraylab/methods.shtml). We used the ABI 7700 system with SYBR Green I dye as reporter and ROX dye as the passive reference (Applied Biosystems, Foster City, CA, USA). For DBC1 measurements, we also used Assays-on-Demand set ID Hs00180893_m1 (Applied Biosystems). A premixed master mix was used for all reactions (Applied Biosystems) and the analysis was performed according to the manufacturer's instructions. Three housekeeping genes were used for normalization (SDHA, GAPDH, HPRT). Primer sequences are available on request.
Senescence assays and induction Senescence status of the transfected cell clones was determined by using b-galactosidase staining at pH 6. A commercial kit was utilized as per the manufacturer's instructions (Cell Signaling Technology, MA, USA). NHU cultures were used as positive controls. The expression levels of Claudin-1 were determined using qRT-PCR (primer sequences are available on request).
In addition, cells were treated with N-acetyl-D-erythro-sphingosine (C 2 ) and N-hexanoyl-D-erythro-sphingosine (C 6 ) (Calbiochem/Merck KgaA, Germany). Two full-length cell clones (clone B and D) and vector control (HA) were treated with 0, 5, 15 and 30 mM of each ceramide, diluted in ethanol. Ethanol concentration corresponding to 30 mM was used as a vehicle control.
